Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D, Papavassillis C, Gelfand J. Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2016 Apr;30(4):645-9. doi: 10.1111/jdv.13478
Hartley L, Girling A, Bowater R, Lilford R. A multistudy analysis investigating systematic differences in cardiovascular trial results between Europe and Asia. J Epidemiol Community Health. 2015 Apr;69(4):397-404. doi: 10.1136/jech-2013-203646
Hartley L, Flowers N, Holmes J, Clarke A, Stranges S, Hooper L. Green and black tea for the primary prevention of cardiovascular disease (CVD): a cochrane systematic review. Poster presented at the Society for Social Medicine conference at the Brighton and Sussex Medical School; September 2013. Brighton, United Kingdom. [abstract] J Epidemiol Community Health. 2013 Sep; 67(Suppl 1):A52-3. doi: 10.1136/jech-2013-203126.109